Search results
City of Hope patients have access to a wide variety of lung cancer clinical trials such as the newest immunotherapy treatment and targeted therapy approaches — all with the goal of helping extend life.
- Cancer Immunotherapeutics - City of Hope
Scientists in City of Hope’s Cancer Immunotherapeutics...
- City of Hope to present leading-edge radiotherapy treatments for people ...
In an early-phase trial, researchers led by Percy Lee, M.D.,...
- Cancer Immunotherapeutics - City of Hope
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the safety and effectiveness of radiation therapy followed by atezolizumab and find out what side effects, if any, it has ...
Scientists in City of Hope’s Cancer Immunotherapeutics Program (CI) are focused on finding new ways to use an old weapon to treat cancer. Researchers here concentrate on discovering new methods of inciting the human immune system to attack tumor cells.
In an early-phase trial, researchers led by Percy Lee, M.D., City of Hope professor of radiation oncology, found that it is safe and effective to treat patients with locally advanced, inoperable non-small cell lung cancer using chemoradiation via a dose-escalated adaptive stereotactic ablative radiotherapy boost in 15 sessions of radiation ...
Patients with advanced non-small cell lung cancer (NSCLC) can experience improved survival when administered immunotherapy over chemotherapy. The first successful immunotherapy treatments developed exploit programmed death 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), immune checkpoint pathways.
24 paź 2024 · Team City of Hope and 5-Year Updated CROWN Data. Presented by Erminia Massarelli, MD, PhD, MS. Investigators presented 5-year efficacy data from the phase 3 CROWN trial (NCT03052608 ) at the 2024 American Society of Clinical Oncology Annual Meeting. 1 The trial assessed patients with ALK -positive NSCLC being treated with lorlatinib (Lorbrena ...
Lung cancer, with non-small cell lung cancer (NSCLC) being the major type, is the second most common malignancy and the leading cause of cancer-related death globally. Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has been one of the greatest advances in recent years for the treatment of solid tumors including NSCLC.
